Genetic analysis of LRRK2 mutations in patients with Parkinson disease
- PMID: 17097110
- DOI: 10.1016/j.jns.2006.09.017
Genetic analysis of LRRK2 mutations in patients with Parkinson disease
Abstract
In addition to the G2019S mutation in the leucine-rich repeat kinase 2 gene (LRRK2), which is particularly frequent in patients of Ashkenazi Jewish and Northern African origin, three amino acid substitutions (R1441C, R1441G, and R1441H), all at the same residue (R1441), have been identified as important genetic causes of Parkinson disease (PD). To evaluate the frequency of R1441C/G/H and G2019S mutations in the LRRK2 gene in North American patients with PD and to explore genotype-phenotype correlations, we screened 496 PD patients from North America. One Hispanic female was heterozygous for the LRRK2 R1441G mutation, and six other cases including 2 non-Jewish/non-Hispanic whites, 3 Ashkenazi Jewish, and 1 Hispanic, were found to be heterozygous for the LRRK2 G2019S mutation. G2019S mutation in the LRRK2 gene is a common mutation associated with PD in a North American population, especially in Jewish PD patients (10.7%), while the R1441C/G/H mutation occurs at a relatively low frequency in North Americans except possibly in Hispanics for R1441G. All six G2019S carriers shared a common haplotype with that observed in Europeans and North Africans. The clinical features of all seven cases with LRRK2 mutation were quite broad and included early and late disease onset. These finding may provide new insights into the cause and diagnosis of PD and have implications for genetic counseling.
Similar articles
-
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.Arch Neurol. 2006 Mar;63(3):377-82. doi: 10.1001/archneur.63.3.377. Arch Neurol. 2006. PMID: 16533964
-
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?Neurology. 2007 Oct 16;69(16):1595-602. doi: 10.1212/01.wnl.0000277637.33328.d8. Neurology. 2007. PMID: 17938369
-
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.Parkinsonism Relat Disord. 2009 May;15(4):277-80. doi: 10.1016/j.parkreldis.2008.06.009. Epub 2008 Sep 20. Parkinsonism Relat Disord. 2009. PMID: 18805725
-
Clinical features of LRRK2 parkinsonism.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Parkinsonism Relat Disord. 2009. PMID: 20082991 Review.
-
LRRK2 G2019S in the North African population: a review.Eur Neurol. 2010;63(6):321-5. doi: 10.1159/000279653. Epub 2010 Apr 23. Eur Neurol. 2010. PMID: 20413974 Review.
Cited by
-
Targeting the progression of Parkinson's disease.Curr Neuropharmacol. 2009 Mar;7(1):9-36. doi: 10.2174/157015909787602814. Curr Neuropharmacol. 2009. PMID: 19721815 Free PMC article.
-
Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.J Neural Transm (Vienna). 2008 Sep;115(9):1279-84. doi: 10.1007/s00702-008-0074-z. Epub 2008 Jul 30. J Neural Transm (Vienna). 2008. PMID: 18665323
-
A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease.Front Aging Neurosci. 2019 Jan 30;11:13. doi: 10.3389/fnagi.2019.00013. eCollection 2019. Front Aging Neurosci. 2019. PMID: 30760999 Free PMC article.
-
Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease.Front Aging Neurosci. 2020 Mar 12;12:12. doi: 10.3389/fnagi.2020.00012. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32226375 Free PMC article.
-
RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes.Nat Commun. 2024 Sep 29;15(1):8434. doi: 10.1038/s41467-024-52723-6. Nat Commun. 2024. PMID: 39343966 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical